3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Histiocytosis
1
Head and Neck Neoplasms
1
Glioblastoma
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Gemcitabine
31
Cisplatin
21
pembrolizumab
8
Fluorouracil
6
Oxaliplatin
5
Capecitabine
5
130-nm albumin-bound paclitaxel
5
durvalumab
4
Taxes
4
Albumin-Bound Paclitaxel
4
pemigatinib
3
infigratinib
3
atezolizumab
3
Specimen Handling
3
Radiosurgery
3
Platinum
3
Magnetic Resonance Spectroscopy
3
Leucovorin
3
Carboplatin
3
Biopsy
3
1,2-diaminocyclohexaneplatinum II citrate
3
tremelimumab
2
trametinib
2
olaparib
2
ivosidenib
2
derazantinib
2
cobimetinib
2
Trastuzumab
2
Radiotherapy
2
Panitumumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Cholangiocarcinoma
×
Immunotherapy
×
Clear all
NCT04989218
2024-11-05
ICC
University of Alabama at Birmingham
Phase 1/2
Terminated
1 enrolled
11 charts